Beijing Konruns Pharmaceutical Co., Ltd. Class ASSE: 603590

Announcement on the Receipt of Clinical Trial Notification for KC1036 Combined with PD-1/PD-L1 Antibody in the Treatment of Advanced Solid Tumors

· Issued by Beijing Konruns Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on the Receipt of Clinical Trial Notification for KC1036 Combined with PD-1/PD-L1 Antibody in the Treatment of Advanced Solid Tumors

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis